目的 观察抗癌平丸联合SOX化疗方案治疗晚期胃癌的临床效果。方法 将2022年2月—2024年10月安庆市第一人民医院收治106例晚期胃癌患者采用随机数字表法分为对照组和治疗组，每组各53例。对照组患者采用SOX化疗方案，第1天静脉滴注注射用奥沙利铂，130 mg/m²加入250 mL 5%葡萄糖溶液，持续滴注2 h；同时口服替吉奥胶囊，体表面积（BSA）＜1.25 m²患者40 mg/次；1.25 m²≤BSA＜1.50 m²患者50 mg/次；BSA≥1.50 m²患者60 mg/次，2次/d；第1～14天口服替吉奥胶囊，第15～21天停药，21 d为1个周期，共治疗4个周期。治疗组在对照组基础上饭后0.5 h口服抗癌平丸，0.5～1.0 g/次，3次/d，连续服用84 d。观察两组患者临床疗效，比较治疗前后两组患者卡氏功能状态量表（KPS）评分和生命质量测定量表（FACT-G）评分，血清糖类抗原72-4（CA72-4）、CA19-9、癌胚抗原（CEA）和CA125水平，及外周血CD3⁺、CD4⁺、CD4⁺/CD8⁺和自然杀伤细胞（NK）水平。结果 治疗后，治疗组患者疾病控制率为84.91%，明显高于对照组的67.92%（P＜0.05）。治疗后，两组KPS评分、FACT-G评分明显高于治疗前（P＜0.05），且治疗组评分明显高于对照组（P＜0.05）。治疗后，两组外周血CD3⁺、CD4⁺/CD8⁺、CD4⁺、NK均低于治疗前，而CD8⁺高于治疗前（P＜0.05），且治疗组外周血免疫功能指标明显好于对照组（P＜0.05）。治疗后，两组患者血清CA72-4、CEA、CA19-9、CA125均低于治疗前（P＜0.05），且治疗组血清胃癌肿瘤标志物水平明显低于对照组（P＜0.05）。治疗组患者不良反应总发生率为18.87%，低于对照组的39.62%（P＜0.05）。结论 抗癌平丸联合SOX化疗方案治疗晚期胃癌可抑制血清肿瘤标志物表达，改善生活质量，提高疾病控制率，减少毒副反应，对免疫功能影响较小。

Objective To observe the clinical effect of study on Kang’aiping Pills combined with SOX chemotherapy regimen in treatment of advanced gastric cancer. Methods Patients (106 cases) with advanced gastric cancer in Anqing First People’s Hospital from February 2022 to October 2024 were divided into control and treatment group according to random number table method, and each group had 53 cases. Patients in the control group were administered with SOX chemotherapy regimen, Oxaliplatin for injection was administered intravenously on the first day, 130 mg/m² was added to 250 mL of 5% glucose solution for 2 h; Gimeracil and Oteracil Potassium Capsules were po administered at the same time, 40 mg/time for patients with BSA < 1.25 m²; 50 mg/time for BSA 1.25 m²≤ BSA < 1.50 m², 60 mg/time for BSA ≥ 1.50 m², twice daily. Gimeracil and Oteracil Potassium Capsules were administered orally on the first day to the 14th day, and the drug was stopped on the 15th to the 21st day. A cycle of 21 d was performed. A total of 4 cycles of treatment were administered. Patients in the treatment group were po administered with Kang’aiping Pills on the basis of the control group 0.5 h after meals, 0.5 — 1.0 g/time, three times daily, they were treated for 84 d. After treatment, the clinical evaluations were evaluated, and the KPS scores and FACT-G scores, the levels of serum CA72-4, CA19-9, CEA and CA125, the levels of peripheral blood CD3⁺, CD4⁺, CD4⁺/CD8⁺ and NK in two groups before and after treatment were compared. Results After treatment, the disease control rate in the treatment group was 84.91%, which was significantly higher than 67.92% in the control group (P < 0.05). After treatment, the KPS score and FACT-G scores in two groups were significantly higher than that before treatment (P < 0.05), and the scores in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, peripheral blood CD3⁺, CD4⁺/CD8⁺, CD4⁺, NK in two groups were lower than before treatment, while CD8⁺ was higher than before treatment (P < 0.05). The peripheral blood immune function indicators in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, serum CA72-4, CEA, CA19-9, and CA125 in two groups were lower than before treatment (P < 0.05), and serum gastric cancer tumor marker levels in the treatment group were significantly lower than those in the control group (P < 0.05). The adverse reaction incidence (18.87%) in the treatment group was lower than that in the control group (39.62%, P < 0.05). Conclusion The combination of Kang’aiping Pills and SOX chemotherapy regimen in the treatment of advanced gastric cancer can inhibit the expression of serum tumor markers, improve the quality of life, increase the disease control rate, reduce toxic and side effects, and has a relatively small impact on immune function.

R979.1

安徽省科学技术研究发展项目（2021D065）